Search results for " sarcomas"

showing 10 items of 11 documents

PML expression in soft tissue sarcoma: Prognostic and predictive value in alkylating agents/antracycline-based first line therapy

2012

Soft tissue sarcomas are aggressive tumors representing <1% of all adult neoplasms. Aim of our study was to evaluate promyelocytic leukemia gene expression value as prognostic factor and as a factor predicting response to alkylating agents/antracycline-based first line therapy. One hundred eleven patients affected by locally advanced and metastatic soft tissue sarcoma were selected. PML expression was evaluated by immunohistochemical analysis in pathological samples and in the corresponding normal tissue from each case. PML immunohistochemical results were correlated with prognosis and with radiological response to alkylating agents/antracycline-based first line therapy. PML expression was …

AdultMaleOncologymedicine.medical_specialtySettore MED/06 - Oncologia MedicaPhysiologyClinical BiochemistryCellDown-RegulationSoft Tissue NeoplasmsPromyelocytic Leukemia ProteinLiposarcomaPleomorphic LiposarcomaYoung AdultPredictive Value of TestsInternal medicinemedicineHumansAnthracyclinesAntineoplastic Agents AlkylatingPathologicalAgedRetrospective StudiesAged 80 and overPMLbusiness.industryTumor Suppressor ProteinsSoft tissue sarcomaNuclear ProteinsSoft tissueSarcomaCell BiologyMiddle AgedPrognosismedicine.diseaseImmunohistochemistrymedicine.anatomical_structuresoft tissue sarcomas; PMLDrug Resistance Neoplasmsoft tissue sarcomaImmunologyImmunohistochemistryFemaleSarcomabusinessTranscription Factors
researchProduct

Retroperitoneale Sarkome: Diagnostik und Therapie

2006

Background Due to the fact that there are no distinct anatomical compartments, retroperitoneal sarcomas are moreover diagnosed with evidence of large tumors and infiltration of adjacent organs. In spite of improvement of the diagnostic facilities and surgical techniques, quite frequently local recurrences with unfavourable prognosis turn up even after complete removal. It was the aim of this study to analyze diagnosis, therapy and long-term prognosis in patients with retroperitoneal sarcomas over a period of 10 years. Patients and methods Between January 1995 and January 2005, 379 patients underwent surgery for a primary retroperitoneal tumor at our clinic. Among the 67 (17.1 %) malignant l…

Leiomyosarcomamedicine.medical_specialtyPathologyRetroperitoneal sarcomasbusiness.industrymedicine.medical_treatmentRetrospective cohort studyLiposarcomamedicine.diseasemedicineSurgeryRadiologyEmbolizationSarcomabusinessSurvival rateNeoadjuvant therapyZentralblatt für Chirurgie
researchProduct

Childhood soft tissue sarcomas incidence and survival in European children (1978-1997): Report from the Automated Childhood Cancer Information System…

2006

This population-based study is based on 5802 cases of soft tissue sarcomas (STS) in children aged 0-14 years extracted from the database of the Automated Childhood Cancer Information System (ACCIS) and registered in population-based cancer registries in Europe for the period 1978-1997. STS represent almost 8% of neoplasms in children, almost half of whom are less than 5 years at diagnosis. Rhabdomyosarcoma is the most frequent childhood STS (50%). During 1988-1997 the age-standardised incidence of STS in Europe was 9.1 per million children, lowest in the West and East and highest in the North. The incidence of STS increased almost 2% per year over the period 1978-1997, attributable mostly t…

MaleCancer Researchmedicine.medical_specialtyPediatricsTime FactorsAdolescentDatabases FactualChildhood - soft tissue sarcomas - incidence and survival - childrenPopulationResidence CharacteristicsEpidemiologymedicineHumansRegistriesMortalityChildeducationRhabdomyosarcomaSurvival analysiseducation.field_of_studybusiness.industryIncidenceIncidence (epidemiology)Soft tissue sarcomaInfant NewbornInfantCancerSarcomamedicine.diseaseSurvival AnalysisEuropeOncologyChild PreschoolFemaleSarcomabusiness
researchProduct

Occupational factors and risk of adult bone sarcomas:a multicentric case-control study in Europe

2006

International audience; We investigated the association between occupational factors and risk of bone sarcoma, a rare tumor with a largely unknown aetiology. A multicentric case-control study was conducted in 7 European countries in 1995-97. Ninety-six cases aged 35-69 years with a centrally reviewed diagnosis of bone sarcoma (68 chondrosarcomas and 28 osteosarcomas) were compared to 2,632 population (68%) or colon cancer (32%) controls. Subjects were interviewed to obtain information on occupational, medical and reproductive history, smoking and alcohol consumption and selected exposures including use of pesticides. Response proportions were 90% among cases and 66% among controls. Odds rat…

MaleCancer ResearchMESH: OsteosarcomaMESH: ReproductionMESH: Occupational Exposure0302 clinical medicineMESH: Risk FactorsRisk FactorsEpidemiologyadult bone sarcomasOdds Ratio030212 general & internal medicineeducation.field_of_studyOsteosarcomaMESH: Middle AgedReproductionResearch Support Non-U.S. Gov'tSmokingMESH: ChondrosarcomaMiddle AgedMESH: Bone NeoplasmsMESH: Interviews as TopicMESH: Case-Control Studies3. Good healthEuropeMulticenter StudyOncology030220 oncology & carcinogenesisColonic NeoplasmsFemaleSarcomamulticentric case-control studyAdultmedicine.medical_specialtyMESH: SmokingAlcohol DrinkingPopulationChondrosarcomaBone NeoplasmsBone SarcomaOccupational medicineInterviews as Topic03 medical and health sciencesInternal medicineOccupational ExposuremedicineJournal ArticlewoodworkersHumansComparative StudyRisk factoreducationMESH: Colonic NeoplasmsMESH: Humansbusiness.industryCase-control studyoccupational risk factorsMESH: AdultOdds ratiopesticidesmedicine.diseaseMESH: MaleMESH: Odds RatioSurgery[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieCase-Control Studies[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieMESH: EuropebusinessMESH: FemaleMESH: Alcohol Drinking
researchProduct

PML down-regulation in soft tissue sarcomas

2010

To date, little is known concerning the promyelocytic leukemia gene (PML) status in tumors of different origin, and its expression has never been evaluated in soft tissue sarcoma. The aim of the present study is focused on the identification of differences in terms of PML protein expression between different types of soft tissue sarcoma and the corresponding normal surrounding tissue. PML protein expression has been assessed by immunohistochemistry in six different histologic types of soft tissue sarcoma (synovial sarcoma, myofibroblastic sarcoma, angiosarcoma, liposarcoma, pleomorphic sarcoma, and leiomyosarcoma) and in the corresponding normal surrounding tissue. PML resulted significantl…

LeiomyosarcomaPathologymedicine.medical_specialtyPhysiologysoft tissue tumorSettore MED/06 - Oncologia MedicaClinical BiochemistryDown-RegulationLiposarcomaPromyelocytic Leukemia ProteinPleomorphic LiposarcomaPML sarcomasPromyelocytic leukemia proteinmedicineHumanssarcomasneoplasmsMyxoid liposarcomaPMLbiologybusiness.industrySoft tissue sarcomaTumor Suppressor ProteinsNuclear ProteinsSarcomaCell BiologyAnatomymedicine.diseaseImmunohistochemistrySynovial sarcomabody regionsbiology.proteinSarcomabusinessTranscription Factors
researchProduct

Next-Generation Sequencing Identifies Potential Actionable Targets in Paediatric Sarcomas

2021

Background: Bone and soft-tissue sarcomas represent 13% of all paediatric malignancies. International contributions to introduce next-generation sequencing (NGS) approaches into clinical application are currently developing. We present the results from the Precision Medicine program for children with sarcomas at a reference centre. Results: Samples of 70 paediatric sarcomas were processed for histopathological analysis, reverse transcriptase polymerase chain reaction (RT-PCR) and next-generation sequencing (NGS) with a consensus gene panel. Pathogenic alterations were reported and, if existing, targeted recommendations were translated to the clinic. Seventy paediatric patients with sarcomas…

0301 basic medicineOncologyCàncer en els infantsmedicine.medical_specialtyprecision medicinetargeted drugslcsh:MedicineMedicine (miscellaneous)Articlepaediatric sarcomasclinical translationDNA sequencinglaw.invention03 medical and health sciences0302 clinical medicinelawInternal medicineGene panelmedicineOssos MalaltiesPolymerase chain reactionPaediatric patientsBiological studiesbusiness.industrylcsh:RHistopathological analysisPrecision medicine030104 developmental biology030220 oncology & carcinogenesisCohortnext-generation sequencingbusinessJournal of Personalized Medicine
researchProduct

Receptor Activator of NF-kB (RANK) Expression in Primary Tumors Associates with Bone Metastasis Occurrence in Breast Cancer Patients

2011

Background\ud Receptor activator of NFkB (RANK), its ligand (RANKL) and the decoy receptor of RANKL (osteoprotegerin, OPG) play a pivotal role in bone remodeling by regulating osteoclasts formation and activity. RANKL stimulates migration of RANK-expressing tumor cells in vitro, conversely inhibited by OPG.\ud \ud Materials and Methods\ud We examined mRNA expression levels of RANKL/RANK/OPG in a publicly available microarray dataset of 295 primary breast cancer patients. We next analyzed RANK expression by immunohistochemistry in an independent series of 93 primary breast cancer specimens and investigated a possible association with clinicopathological parameters, bone recurrence and surviv…

Anatomy and PhysiologyMicroarraysSettore MED/06 - Oncologia MedicaCancer TreatmentLigandsMetastasisBone remodelingMetastasisBasic Cancer ResearchBreast TumorsBone and Soft Tissue SarcomasNeoplasm MetastasisMusculoskeletal SystemOligonucleotide Array Sequence AnalysisMultidisciplinaryPredictive markerReceptor Activator of Nuclear Factor-kappa BQRBone metastasisMiddle AgedImmunohistochemistryGene Expression Regulation NeoplasticOncologyRANKLMedicineFemaleResearch Articlemusculoskeletal diseasesmedicine.medical_specialtyHistologyScienceBone NeoplasmsBreast NeoplasmsBiologyBreast cancerAntibody TherapySDG 3 - Good Health and Well-beingOsteoprotegerinInternal medicinemedicineHumansRNA MessengerBoneBiologyAgedBreast cancer bone metastasis RANK-RANKLRANK LigandOsteoprotegerinComputational BiologyCancers and NeoplasmsRANK Ligandmedicine.diseaseEndocrinologyCancer researchbiology.protein
researchProduct

Olaratumab: PDGFR-α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas

2017

Advanced soft tissue sarcomas are aggressive cancers with limited therapeutic options. Recently, inhibition of platelet-derived growth factor receptor (PDGFR)-α by the monoclonal antibody olaratumab showed promising clinical activity. If confirmed, this would be one of the first examples of targeted therapy effective in advanced soft tissue sarcomas therapy independently of the histologic subtype. Here, we reviewed the biology of the PDGF/PDGFR axis, particularly focusing on its role in cancer, and then we discussed on the effects of PDGFR-α inhibition in the therapy of advanced soft tissue sarcomas.

0301 basic medicinemedicine.medical_specialtyPathologyReceptor Platelet-Derived Growth Factor alphamedicine.medical_treatmentPDGFR-αAntineoplastic AgentsTargeted therapy03 medical and health sciences0302 clinical medicineGrowth factor receptorDoxorubicin; Olaratumab; PDGFR-α; Soft tissue sarcomas; Hematology; Oncology; Geriatrics and GerontologyInternal medicinemedicineHumansDoxorubicinOlaratumabSoft tissue sarcomaHematologybiologybusiness.industryAntibodies MonoclonalCancerSoft tissueSarcomaHematologySoft tissue sarcomasmedicine.disease030104 developmental biologyOncologyDoxorubicin030220 oncology & carcinogenesisbiology.proteinGeriatrics and GerontologybusinessPlatelet-derived growth factor receptormedicine.drugOlaratumab
researchProduct

CHEMO-RESISTANT SOFT-TISSUE SARCOMAS (STS). Experience of the Italian Cooperative Study (ICS)

1993

The purpose of this study is to evaluete the Italian experience about localized Fivrosarcomas (FS) and Neurogenic Darcomas (NS)

Settore MED/38 - Pediatria Generale E SpecialisticaSettore MED/20 - Chirurgia Pediatrica E InfantilePaediatric tumours Soft Tissue Sarcomas
researchProduct

ROLE of SURGERY for NONMETASTATIC ABDOMINAL RRHABDOMYOSARCOMAS. A Report from the Italian and German Cooperative Groups Studies.

2003

In the current study, the Authors aim to evaluate clinical features and treatment results observed in patients from the German and Italian studies who had nonmetastatic abdominal rhabdomyosarcomas.

Settore MED/38 - Pediatria Generale E SpecialisticaSettore MED/20 - Chirurgia Pediatrica E InfantilePediatric Soft tissue sarcomas rhabdomyosarcomas surgery abdomen
researchProduct